Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
Total Valuation
Entrada Therapeutics Inc has a market cap or net worth of $332.34M. The enterprise value is $383.55M.
Market Cap$332.34M
Enterprise Value$383.55M
Share Statistics
Entrada Therapeutics Inc has 37,594,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,594,630
Owned by Insiders41.03%
Owned by Institutions0.04%
Financial Efficiency
Entrada Therapeutics Inc’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee1.15M
Profits Per Employee358.61K
Employee Count183
Asset Turnover0.40
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Entrada Therapeutics Inc is 9.83. Entrada Therapeutics Inc’s PEG ratio is -0.01.
PE Ratio9.83
PS Ratio1.87
PB Ratio1.50
Price to Fair Value1.50
Price to FCF-14.43
Price to Operating Cash Flow-15.52
PEG Ratio-0.01
Income Statement
In the last 12 months, Entrada Therapeutics Inc had revenue of 210.78M and earned 65.63M in profits. Earnings per share was 1.76.
Revenue210.78M
Gross Profit210.78M
Operating Income47.01M
Pretax Income66.48M
Net Income65.63M
EBITDA47.01M
Earnings Per Share (EPS)1.76
Cash Flow
In the last 12 months, operating cash flow was -41.56M and capital expenditures -3.16M, giving a free cash flow of -44.72M billion.
Operating Cash Flow-41.56M
Free Cash Flow-44.72M
Free Cash Flow per Share-1.19
Dividends & Yields
Entrada Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change-28.36%
50-Day Moving Average10.16
200-Day Moving Average14.88
Relative Strength Index (RSI)47.88
Average Volume (3m)150.23K
Important Dates
Entrada Therapeutics Inc upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Entrada Therapeutics Inc as a current ratio of 11.15, with Debt / Equity ratio of 13.81%
Current Ratio11.15
Quick Ratio11.15
Debt to Market Cap0.09
Net Debt to EBITDA―
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Entrada Therapeutics Inc has paid 859.00K in taxes.
Income Tax859.00K
Effective Tax Rate0.01
Enterprise Valuation
Entrada Therapeutics Inc EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Entrada Therapeutics Inc has $420.00M in cash and marketable securities with $59.21M in debt, giving a net cash position of -$360.79M billion.
Cash & Marketable Securities$420.00M
Total Debt$59.21M
Net Cash-$360.79M
Net Cash Per Share-$9.60
Tangible Book Value Per Share$11.49
Margins
Gross margin is 98.70%, with operating margin of 22.30%, and net profit margin of 31.13%.
Gross Margin98.70%
Operating Margin22.30%
Pretax Margin31.54%
Net Profit Margin31.13%
EBITDA Margin22.30%
EBIT Margin22.30%
Analyst Forecast
The average price target for Entrada Therapeutics Inc is $24.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$24.33
Price Target Upside175.23% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast63.38%
EPS Growth Forecast―